Atherosclerotic renal artery stenosis is commonly present in patients with clinically manifest atherosclerosis in other vascular beds and is independently associated with increased cardiovascular morbidity and mortality. Screening tests such as renal angiography should be selectively applied to patients at high risk for renal artery stenosis who are potential candidates for revascularization. This multispecialty consensus document describes the rationale for patient selection for screening renal angiography at the time of cardiac catheterization. (Circulation. 2006;114:1892-1895.) Key Words: AHA Scientific Statements Ⅲ arteriography Ⅲ atherosclerotic renal artery stenosis Ⅲ atherosclerosis Ⅲ hypertension, renal
A therosclerotic renal artery stenosis (ARAS) is a common anatomic finding in patients with atherosclerosis in other arterial circulations. 1 This science advisory will address the appropriate use of diagnostic screening arteriography for ARAS at the time of coronary arteriography, pejoratively called "drive-by renal arteriography," in patients at increased risk for ARAS (Tables 1 and 2) who have clinical indications for renal artery revascularization as defined in the recently published American College of Cardiology/American Heart Association (ACC/AHA) guidelines for management of peripheral vascular disease. 3 The association between ARAS and peripheral arterial atherosclerosis is well established, occurring in 22% to 59% of cases. 5, 6 This frequency of concomitant disease explains why abdominal aortography with run-off for lower-extremity ischemic disease routinely includes imaging of the renal arteries. There is also a marked increase in the prevalence of ARAS in patients with known or suspected coronary artery disease [7] [8] [9] (Table 3 ). In the largest series of screening renal arteriography, 1235 unselected, consecutive patients had both coronary arteriography and abdominal aortography. 9 Thirty percent of patients were found to have some evidence of ARAS, and 15% had lesions Ն50% diameter stenosis. In a selected population of 297 hypertensive patients referred for coronary arteriography who also had concurrent abdominal aortography during the same procedure, 34% had evidence of renal artery stenosis, and 19% had ARAS lesions Ն50% diameter stenosis. 11 Bilateral ARAS was noted in 19% to 29% of patients with Ն50% ARAS ( Table 3 ).
The diagnosis of ARAS, even if not hemodynamically significant, provides information that affects patient management. ARAS is associated with premature cardiovascular events (myocardial infarction, stroke, and death), and the presence of ARAS in patients with coronary disease independently doubles a patient's risk of mortality even when coronary revascularization is performed. 12 The increase in mortality is directly related to the severity of ARAS: The more severe the stenosis, the higher the mortality risk. The
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presence of bilateral ARAS significantly reduced 4-year survival in affected patients to 47% compared with 59% (PϽ0.001) in patients with unilateral ARAS. 12 Progression or worsening of ARAS occurs commonly, with occlusion and loss of renal function more likely with more severe renal stenoses. 13, 14 Sequential coronary and abdominal aortography performed in 1189 patients, with an average of 2.6Ϯ1.6 years between studies, demonstrated progression of ARAS in 11.1% of patients. 13 Patients with normal renal arteries at baseline who demonstrated progression to severe ARAS (Ն75%) had significant deterioration in their renal function compared with those without progression of ARAS. 13 Serial ultrasound studies in patients with ARAS confirmed that lesion progression occurred in about one third of 295 arteries serially imaged over 3 years, but that progression to occlusion only occurred if baseline ARAS was Ͼ60%. 14 A randomized trial of hypertensive patients with ARAS lesions Ն50% demonstrated that 16% of the medical treatment group had progressed to occlusion at 1 year. 15 The cost or risk versus the benefit of performing screening renal arteriography at the time of diagnostic coronary arteriography in patients with indications for renal revasculariza-tion must be considered. Although aortography does add cost to the coronary angiographic procedure, it is comparable to the cost of the noninvasive imaging test that it replaces. There is good evidence that the addition of abdominal aortography to coronary arteriography in patients with a baseline serum creatinine Յ2.0 mg/dL is not associated with an increase in procedure-related morbidity or mortality. 11 In a series of 297 patients with hypertension undergoing coronary arteriography and concurrent abdominal aortography, no patients experienced deterioration in renal function, clinical atheromatous embolization, or prolongation in the length of hospital stay. 11 The additional contrast administration is negligible, and the catheter used for nonselective renal arteriography is atraumatic. Patients at increased risk for contrast-induced nephropathy should be pretreated with N-acetylcysteine and receive vigorous hydration before the administration of low-osmolar contrast. 3 Ideally, patients with a clinical indication for investigation of renal artery patency will undergo a noninvasive diagnostic test (duplex ultrasonography, magnetic resonance arteriography, or computer-assisted tomographic arteriography) before diagnostic coronary arteriography. However, some patients at "high risk" for ARAS (Table 1) who are potential candidates for renal revascularization will present for urgent coronary arteriography without having had the opportunity for noninvasive screening for ARAS.
The increased prevalence of ARAS in patients with coronary artery disease and the poor prognosis independently associated with the presence of ARAS supports a strategy of increased awareness of this disease process and a need to • Unexplained congestive heart failure or refractory angina (Class IIb; LOE C) ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; LOE, level of evidence (see Table 2 ).
*For definition of hypertension, see Chobanian et al. 2 †For example, a kidney that has become atrophic owing to chronic pyelonephritis is not an indication for renal artery stenosis evaluation.
Reprinted identify ARAS as early as possible. We conclude that it is reasonable to perform screening renal arteriography at the time of cardiac catheterization in patients at increased risk for ARAS (Table 1) who are candidates for revascularization as defined in the ACC/AHA peripheral arterial disease management guideline document. 3 
